ArticleESC heart failure2021
Impact of diastolic dysfunction on outcome in heart failure patients with mid-range or reduced ejection fraction.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis.ESC heart failure · 2022Pooled it
- Accuracy of Emergency Physicians in Grading Diastolic Dysfunction Using Visual Estimation of Waveforms.The western journal of emergency medicine · 2026Article
- Arterio-venous gradient of active interleukin-18 is associated with diastolic dysfunction: a cross-sectional study.ESC heart failure · 2026Article
- The prognostic importance of left ventricular diastolic function in primary mitral regurgitation and its relation to structural changes by CMR.Scientific reports · 2025Article
- Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy.ESC heart failure · 2025Observational
- Article
- Echocardiographic predictors of outcome in severe aortic stenosis patients with preserved or reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Impact of atrial fibrillation on cerebro-cardiovascular outcome of heart failure with mildly-reduced ejection fraction.ESC heart failure · 2023Article
- Potential role of left atrial strain in estimation of left atrial pressure in patients with chronic heart failure.ESC heart failure · 2023Article
- Cardiometabolic Phenotyping in Heart Failure: Differences between Patients with Reduced vs. Preserved Ejection Fraction.Diagnostics (Basel, Switzerland) · 2023Article
- Risk factors of short-term, intermediate-term, and long-term cardiac events in patients hospitalized for HFmrEF.ESC heart failure · 2022Article
- Impact of Myocardial Energy Expenditure and Diastolic Dysfunction on One Year Outcome Patients With HFpEF.Frontiers in physiology · 2022Article
- Echocardiographic risk factors of left ventricular thrombus in patients with acute anterior myocardial infarction.ESC heart failure · 2021Article
- Impact of diastolic dysfunction on outcome in heart failure patients with mid-range or reduced ejection fraction.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe role of diastolic dysfunction (DD) in prognostic evaluation in heart failure (HF) patients with impaired systolic function remains unclear. We investigated the impact of echocardiography-defined DD on survival in HF patients with mid-range (HFmrEF, EF 41-49%) and reduced ejection fraction (HFrEF, EF < 40%). METHODS AND
resultsA total of 2018 consecutive hospitalized HF patients were retrospectively included and divided in two groups based on baseline EF: HFmrEF group (n = 951, aged 69 ± 13 years, 74.2% male) and HFrEF group (n = 1067, aged 68 ± 13 years, 76.3% male). Clinical data were collected and analysed. All patients completed ≥1 year clinical follow-up. The primary endpoint was defined as all-cause death (including heart transplantation) and cardiovascular (CV)-related death. All-cause mortality (30.8% vs. 24.9%, P = 0.003) and CV mortality (19.1% vs. 13.5%, P = 0.001) were significantly higher in the HFrEF group than the HFmrEF group during follow-up [median 24 (13-36) months]. All-cause mortality increased in proportion to DD severity (mild, moderate, and severe) in either HFmrEF (17.1%, 25.4%, and 37.0%, P < 0.001) or HFrEF (18.9%, 30.3%, and 39.2%, P < 0.001) patients. The risk of all-cause mortality [hazard ratio (HR) = 1.347, P = 0.015] and CV mortality (HR = 1.508, P = 0.007) was significantly higher in HFrEF patients with severe DD compared with non-severe DD after adjustment for identified clinical and echocardiographic covariates. For HFmrEF patients, severe DD was independently associated with increased all-cause mortality (HR = 1.358, P = 0.046) but not with CV mortality (HR = 1.155, P = 0.469).
conclusionsEchocardiography-defined severe DD is independently associated with increased all-cause mortality in patients with HFmrEF and HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.